Identification

Name
Pitavastatin
Accession Number
DB08860  (DB06514)
Type
Small Molecule
Groups
Approved
Description

Pitavastatin a lipid-lowering agent that belongs to the statin class of medications for treatment of dyslipidemia. It is also used for primary and secondary prevention of cardiovascular disease. FDA approved in Aug 3, 2009.

Structure
Thumb
Synonyms
  • Pitavastatia
  • Pitavastatine
  • Pitavastatinum
External IDs
NK 104 / NK-104 / NKS-104 / NKS104
Product Ingredients
IngredientUNIICASInChI Key
Pitavastatin CalciumIYD54XEG3W147526-32-7RHGYHLPFVJEAOC-WUVPNHNWSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LivaloTablet, film coated1 mg/1OralEli Lilly & Co. Ltd.2010-05-152016-10-13Us00002 4770 90 nlmimage10 9516caa6
LivaloTablet, film coated1.045 mg/1OralKowa Company, Ltd.2010-05-15Not applicableUs66869 0104 90 nlmimage10 323c1910
LivaloTablet, film coated2 mg/1OralEli Lilly & Co. Ltd.2010-05-152016-10-13Us00002 4771 90 nlmimage10 8f16c7a6
LivaloTablet, film coated2.09 mg/1OralKowa Company, Ltd.2010-05-15Not applicableUs66869 0204 90 nlmimage10 293c1490
LivaloTablet, film coated4 mg/1OralEli Lilly & Co. Ltd.2010-05-152016-10-13Us00002 4772 90 nlmimage10 8c16c656
LivaloTablet, film coated4.18 mg/1OralKowa Company, Ltd.2010-05-15Not applicableUs66869 0404 90 nlmimage10 d93c6ce3
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PitavastatinTablet, film coated1.045 mg/1OralOrient Pharma Co., Ltd.2016-01-292017-07-24Us
PitavastatinTablet, film coated2.09 mg/1OralOrient Pharma Co., Ltd.2016-01-292017-07-24Us
PitavastatinTablet, film coated4.18 mg/1OralOrient Pharma Co., Ltd.2016-01-292017-07-24Us
Categories
UNII
M5681Q5F9P
CAS number
147511-69-1
Weight
Average: 421.4608
Monoisotopic: 421.168936466
Chemical Formula
C25H24FNO4
InChI Key
VGYFMXBACGZSIL-MCBHFWOFSA-N
InChI
InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1
IUPAC Name
(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
SMILES
O[[email protected]](C[[email protected]](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O

Pharmacology

Indication

Pitavastatin is used to lower serum levels of total cholesterol, LDL-C, apolipoprotein B, and triglycerides, and raise levels of HDL-C for the treatment of dyslipidemia.

Structured Indications
Pharmacodynamics

The magnitude of LDL-C reduction by pitavastatin (2 mg and 4 mg) is comparable to atorvastatin (10 mg and 20 mg) and simvastatin (20 mg and 40 mg). It also does not prolong the QTc interval to a clinically significant degree.

Mechanism of action

Pitavastatin is lipid-lowering agent that works to control the synthesis of cholesterol via competitive inhibition of the liver enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. As a result, a compensatory increase in LDL-receptor expression can be observed which facilitates an increase LDL catabolism.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
Absorption

Bioavailability = 51%; Time to peak, plasma = 1 hour; Pitavastatin was absorbed in the small intestine but very little in the colon. Cmax decreases by 43% if pitavastatin is taken with a fatty meal but there are no significant changes to AUC or baseline LDL levels compared to fasting state. The Cmax and AUC of pitavastatin did not differ following evening or morning drug administration.

Volume of distribution

148 L

Protein binding

>99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein.

Metabolism

Pitavastatin is mainly metabolized by liver. It undergoes glucuronidation by uridine 5-diphosphate glucuronosyl transferases (UGT1A3 and UGT2B7) to form the major circulating metabolite, pitavastatin lactone.

The cytochrome P450 system has little involvement with the metabolism of pitavastatin. There is some metabolism by CYP2C9 and to a lesser extent, CYP2C8. Studies suggest that concomitant therapy with drugs that are involved with the cytochrome P450 system will not effect the pharmacokinetics of pitavastatin.

Route of elimination

79% in feces and 15% excreted in urine.

Half life

Plasma elimination half-lfie = 12 hours

Clearance

CL/F (apparent clearance), 4 mg, healthy male Korean subjects = 23.6 L/h

Toxicity

The most frequent adverse reactions (rate ≥2.0% in at least one marketed dose) were myalgia, back pain, diarrhea, constipation and pain in extremity.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe risk or severity of adverse effects can be increased when Abafungin is combined with Pitavastatin.Investigational
AbirateroneThe serum concentration of Pitavastatin can be increased when it is combined with Abiraterone.Approved
AcenocoumarolPitavastatin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Pitavastatin can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Pitavastatin can be increased when it is combined with Acetazolamide.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Pitavastatin.Approved, Investigational
AlbaconazoleThe risk or severity of adverse effects can be increased when Albaconazole is combined with Pitavastatin.Investigational
AldesleukinThe serum concentration of Pitavastatin can be increased when it is combined with Aldesleukin.Approved
AlmasilateThe serum concentration of Pitavastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Pitavastatin can be decreased when it is combined with Aloglutamol.Experimental
AlprazolamThe serum concentration of Pitavastatin can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AluminiumThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminum hydroxide.Approved
AmbroxolThe serum concentration of Pitavastatin can be increased when it is combined with Ambroxol.Approved, Investigational
AmiodaroneThe metabolism of Pitavastatin can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Pitavastatin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Pitavastatin can be increased when it is combined with Amprenavir.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Pitavastatin.Approved
AnastrozoleThe serum concentration of Pitavastatin can be increased when it is combined with Anastrozole.Approved, Investigational
AntipyrineThe serum concentration of Pitavastatin can be increased when it is combined with Antipyrine.Approved
AprepitantThe metabolism of Pitavastatin can be increased when combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Pitavastatin can be increased when it is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Pitavastatin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Pitavastatin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Pitavastatin can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Pitavastatin can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Pitavastatin can be increased when it is combined with Azelastine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Pitavastatin.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Pitavastatin.Investigational
AzithromycinThe serum concentration of Pitavastatin can be increased when it is combined with Azithromycin.Approved
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Pitavastatin.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Pitavastatin.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Pitavastatin.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Pitavastatin.Approved, Withdrawn
BetamethasoneThe serum concentration of Pitavastatin can be increased when it is combined with Betamethasone.Approved, Vet Approved
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Pitavastatin.Approved
BicalutamideThe serum concentration of Pitavastatin can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Pitavastatin can be increased when it is combined with Bifonazole.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Pitavastatin can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Pitavastatin can be decreased when it is combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Pitavastatin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Pitavastatin can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Pitavastatin can be increased when combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe serum concentration of Pitavastatin can be increased when it is combined with Brentuximab vedotin.Approved
BromocriptineThe serum concentration of Pitavastatin can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Pitavastatin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Pitavastatin.Approved
CabergolineThe serum concentration of Pitavastatin can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Pitavastatin can be increased when it is combined with Caffeine.Approved
Calcium CarbonateThe serum concentration of Pitavastatin can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Pitavastatin can be decreased when it is combined with Calcium silicate.Experimental
CapecitabineThe metabolism of Pitavastatin can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe serum concentration of Pitavastatin can be increased when it is combined with Capsaicin.Approved
CarbamazepineThe metabolism of Pitavastatin can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Pitavastatin.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Pitavastatin.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Pitavastatin.Experimental
CaspofunginThe serum concentration of Pitavastatin can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Pitavastatin can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Pitavastatin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cerivastatin.Withdrawn
ChloramphenicolThe serum concentration of Pitavastatin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Pitavastatin can be increased when it is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Pitavastatin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pitavastatin.Approved, Investigational
CilostazolThe serum concentration of Pitavastatin can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Pitavastatin can be increased when it is combined with Cimetidine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Pitavastatin.Approved, Investigational
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Pitavastatin.Approved, Investigational
CiprofloxacinThe serum concentration of Pitavastatin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Pitavastatin can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Pitavastatin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Pitavastatin can be increased when it is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Pitavastatin.Approved
ClindamycinThe serum concentration of Pitavastatin can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe serum concentration of Pitavastatin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Pitavastatin can be increased when it is combined with Clomifene.Approved, Investigational
ClorindionePitavastatin may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe serum concentration of Pitavastatin can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Pitavastatin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Pitavastatin can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Pitavastatin can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Pitavastatin can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Pitavastatin.Approved
ConivaptanThe serum concentration of Pitavastatin can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe serum concentration of Pitavastatin can be increased when it is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Pitavastatin can be decreased when combined with Crisaborole.Approved
CrizotinibThe serum concentration of Pitavastatin can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Pitavastatin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Pitavastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pitavastatin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Pitavastatin can be increased when it is combined with Daclatasvir.Approved
DalfopristinThe serum concentration of Pitavastatin can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Pitavastatin can be increased when it is combined with Danazol.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Pitavastatin is combined with Daptomycin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Pitavastatin.Experimental
DarunavirThe serum concentration of Pitavastatin can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Pitavastatin can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Pitavastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Pitavastatin can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Pitavastatin can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Pitavastatin can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Pitavastatin can be increased when it is combined with Desipramine.Approved
DexamethasoneThe serum concentration of Pitavastatin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextropropoxypheneThe serum concentration of Pitavastatin can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Pitavastatin can be increased when it is combined with Diazepam.Approved, Illicit, Vet Approved
DicoumarolPitavastatin may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Pitavastatin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DihydroergotamineThe serum concentration of Pitavastatin can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Pitavastatin can be increased when it is combined with Diltiazem.Approved
Dimethyl sulfoxideThe serum concentration of Pitavastatin can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DiphenadionePitavastatin may increase the anticoagulant activities of Diphenadione.Experimental
DocetaxelThe serum concentration of Pitavastatin can be increased when it is combined with Docetaxel.Approved, Investigational
DosulepinThe metabolism of Pitavastatin can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Pitavastatin.Investigational
DoxorubicinThe serum concentration of Pitavastatin can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Pitavastatin can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Pitavastatin can be increased when it is combined with Dronedarone.Approved
EconazoleThe serum concentration of Pitavastatin can be increased when it is combined with Econazole.Approved
EfavirenzThe metabolism of Pitavastatin can be decreased when combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Pitavastatin.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pitavastatin.Approved, Investigational
ElbasvirThe serum concentration of Pitavastatin can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Pitavastatin can be increased when it is combined with Eltrombopag.Approved
EnasidenibThe serum concentration of Pitavastatin can be increased when it is combined with Enasidenib.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Pitavastatin.Approved, Investigational
EpinephrineThe serum concentration of Pitavastatin can be increased when it is combined with Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe serum concentration of Pitavastatin can be increased when it is combined with Ergoloid mesylate.Approved
ErgonovineThe serum concentration of Pitavastatin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Pitavastatin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Pitavastatin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EthanolThe serum concentration of Pitavastatin can be increased when it is combined with Ethanol.Approved
Ethyl biscoumacetatePitavastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideThe serum concentration of Pitavastatin can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Pitavastatin can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Pitavastatin can be decreased when it is combined with Etravirine.Approved
EzetimibeThe serum concentration of Pitavastatin can be increased when it is combined with Ezetimibe.Approved
FelodipineThe metabolism of Pitavastatin can be decreased when combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Pitavastatin.Withdrawn
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Pitavastatin.Approved
FentanylThe serum concentration of Pitavastatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Pitavastatin.Experimental
FidaxomicinThe risk or severity of adverse effects can be increased when Fidaxomicin is combined with Pitavastatin.Approved
FloxuridineThe metabolism of Pitavastatin can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Pitavastatin can be decreased when combined with Fluconazole.Approved
FluindionePitavastatin may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pitavastatin.Approved
FluorouracilThe metabolism of Pitavastatin can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Pitavastatin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
Fluticasone propionateThe serum concentration of Pitavastatin can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Pitavastatin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Pitavastatin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Pitavastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pitavastatin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Pitavastatin can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe risk or severity of adverse effects can be increased when Fusidic Acid is combined with Pitavastatin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pitavastatin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Pitavastatin.Investigational
GemfibrozilGemfibrozil may increase the myopathic rhabdomyolysis activities of Pitavastatin.Approved
GlyburideThe serum concentration of Pitavastatin can be increased when it is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Pitavastatin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
HaloperidolThe serum concentration of Pitavastatin can be increased when it is combined with Haloperidol.Approved
HistamineThe serum concentration of Pitavastatin can be increased when it is combined with Histamine.Approved, Investigational
HydralazineThe serum concentration of Pitavastatin can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Pitavastatin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrotalciteThe serum concentration of Pitavastatin can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
IdelalisibThe serum concentration of Pitavastatin can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Pitavastatin can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Pitavastatin can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Pitavastatin can be increased when it is combined with Imatinib.Approved
IndinavirThe metabolism of Pitavastatin can be decreased when combined with Indinavir.Approved
indisulamThe serum concentration of Pitavastatin can be increased when it is combined with indisulam.Investigational
IrbesartanThe metabolism of Pitavastatin can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Pitavastatin can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe risk or severity of adverse effects can be increased when Isavuconazole is combined with Pitavastatin.Approved, Investigational
IsavuconazoniumThe serum concentration of Pitavastatin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Pitavastatin.Approved
IsoniazidThe serum concentration of Pitavastatin can be increased when it is combined with Isoniazid.Approved
IsradipineThe serum concentration of Pitavastatin can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Pitavastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pitavastatin can be increased when it is combined with Ivacaftor.Approved
JosamycinThe serum concentration of Pitavastatin can be increased when it is combined with Josamycin.Approved, Investigational
KetazolamThe serum concentration of Pitavastatin can be increased when it is combined with Ketazolam.Approved
KetoconazoleThe metabolism of Pitavastatin can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Pitavastatin.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Pitavastatin.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pitavastatin.Approved, Investigational
LansoprazoleThe serum concentration of Pitavastatin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Pitavastatin.Approved
LapatinibThe metabolism of Pitavastatin can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Pitavastatin can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineThe serum concentration of Pitavastatin can be increased when it is combined with Lercanidipine.Approved, Investigational
LevofloxacinThe serum concentration of Pitavastatin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Pitavastatin can be increased when it is combined with Levosalbutamol.Approved
LidocaineThe serum concentration of Pitavastatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Pitavastatin.Experimental
LinagliptinThe serum concentration of Pitavastatin can be increased when it is combined with Linagliptin.Approved
LobeglitazoneThe metabolism of Pitavastatin can be decreased when combined with Lobeglitazone.Approved, Investigational
LomitapideThe serum concentration of Pitavastatin can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of Pitavastatin can be increased when it is combined with Lomustine.Approved
LopinavirThe serum concentration of Pitavastatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Pitavastatin can be increased when it is combined with Loratadine.Approved
LosartanThe metabolism of Pitavastatin can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Pitavastatin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pitavastatin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pitavastatin can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe serum concentration of Pitavastatin can be increased when it is combined with Lurasidone.Approved
MagaldrateThe serum concentration of Pitavastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Pitavastatin.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Pitavastatin can be decreased when combined with Manidipine.Approved, Investigational
MefloquineThe serum concentration of Pitavastatin can be increased when it is combined with Mefloquine.Approved
MequitazineThe serum concentration of Pitavastatin can be increased when it is combined with Mequitazine.Approved
MethadoneThe serum concentration of Pitavastatin can be increased when it is combined with Methadone.Approved
MethazolamideThe serum concentration of Pitavastatin can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Pitavastatin can be increased when it is combined with Methimazole.Approved
MethylergometrineThe serum concentration of Pitavastatin can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Pitavastatin can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MetronidazoleThe serum concentration of Pitavastatin can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Pitavastatin can be increased when it is combined with Metyrapone.Approved
MibefradilThe serum concentration of Pitavastatin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Pitavastatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Pitavastatin can be increased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Pitavastatin can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Pitavastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe serum concentration of Pitavastatin can be increased when it is combined with Mirtazapine.Approved
MitoxantroneThe serum concentration of Pitavastatin can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Pitavastatin can be increased when it is combined with Modafinil.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Pitavastatin.Investigational
NefazodoneThe serum concentration of Pitavastatin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Pitavastatin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Pitavastatin can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Pitavastatin can be increased when it is combined with Nevirapine.Approved
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Pitavastatin.Approved, Investigational, Nutraceutical
NicardipineThe metabolism of Pitavastatin can be decreased when combined with Nicardipine.Approved
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Pitavastatin.Approved
NifedipineThe serum concentration of Pitavastatin can be increased when it is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Pitavastatin.Experimental
NilotinibThe metabolism of Pitavastatin can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Pitavastatin.Experimental
NilvadipineThe serum concentration of Pitavastatin can be increased when it is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pitavastatin.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Pitavastatin.Approved
NisoldipineThe serum concentration of Pitavastatin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe serum concentration of Pitavastatin can be increased when it is combined with Nitric Oxide.Approved
NorfloxacinThe serum concentration of Pitavastatin can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Pitavastatin can be increased when it is combined with Noscapine.Investigational
OlanzapineThe serum concentration of Pitavastatin can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Pitavastatin can be increased when it is combined with Olaparib.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Pitavastatin.Vet Approved
OmbitasvirThe serum concentration of Pitavastatin can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe metabolism of Pitavastatin can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Pitavastatin.Experimental
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Pitavastatin.Experimental, Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Pitavastatin.Approved
OxybutyninThe serum concentration of Pitavastatin can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Pitavastatin can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe serum concentration of Pitavastatin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Pitavastatin can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe serum concentration of Pitavastatin can be increased when it is combined with Paramethasone.Approved
ParitaprevirThe serum concentration of Pitavastatin can be increased when it is combined with Paritaprevir.Approved
PazopanibPitavastatin may increase the hepatotoxic activities of Pazopanib.Approved
PergolideThe serum concentration of Pitavastatin can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Pitavastatin.Approved, Investigational
PhenelzineThe serum concentration of Pitavastatin can be increased when it is combined with Phenelzine.Approved
PhenindionePitavastatin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Pitavastatin can be increased when combined with Phenobarbital.Approved
PhenprocoumonPitavastatin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe serum concentration of Pitavastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pitavastatin can be increased when it is combined with Pilocarpine.Approved
PimozideThe serum concentration of Pitavastatin can be increased when it is combined with Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Pitavastatin.Approved
PioglitazoneThe metabolism of Pitavastatin can be decreased when combined with Pioglitazone.Approved, Investigational
PosaconazoleThe serum concentration of Pitavastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pitavastatin can be increased when it is combined with Pravastatin.Approved
PrednisoloneThe serum concentration of Pitavastatin can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Pitavastatin can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pitavastatin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Pitavastatin.Withdrawn
PrimaquineThe serum concentration of Pitavastatin can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Pitavastatin can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Pitavastatin can be increased when it is combined with Progesterone.Approved, Vet Approved
PropofolThe serum concentration of Pitavastatin can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PyrimethamineThe metabolism of Pitavastatin can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinidineThe serum concentration of Pitavastatin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Pitavastatin can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Pitavastatin can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe metabolism of Pitavastatin can be decreased when combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Pitavastatin can be increased when it is combined with Raloxifene.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Pitavastatin.Approved
RanitidineThe serum concentration of Pitavastatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Pitavastatin can be increased when it is combined with Ranolazine.Approved, Investigational
RavuconazoleThe risk or severity of adverse effects can be increased when Ravuconazole is combined with Pitavastatin.Investigational
RegorafenibThe serum concentration of Pitavastatin can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Pitavastatin can be increased when it is combined with Repaglinide.Approved, Investigational
ResveratrolThe serum concentration of Pitavastatin can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RifabutinThe serum concentration of Pitavastatin can be increased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Pitavastatin can be increased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Pitavastatin can be increased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Pitavastatin can be increased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Pitavastatin can be increased when it is combined with Rilpivirine.Approved
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Pitavastatin.Approved, Investigational
RisperidoneThe serum concentration of Pitavastatin can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Pitavastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Pitavastatin can be increased when it is combined with Rivastigmine.Approved, Investigational
RolapitantThe serum concentration of Pitavastatin can be increased when it is combined with Rolapitant.Approved
RolitetracyclineThe serum concentration of Pitavastatin can be increased when it is combined with Rolitetracycline.Approved
RosiglitazoneThe metabolism of Pitavastatin can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Pitavastatin can be increased when it is combined with Rosuvastatin.Approved
RoxithromycinThe serum concentration of Pitavastatin can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RutinThe serum concentration of Pitavastatin can be increased when it is combined with Rutin.Experimental, Investigational
SalbutamolThe serum concentration of Pitavastatin can be increased when it is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe serum concentration of Pitavastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe serum concentration of Pitavastatin can be increased when it is combined with Sarilumab.Approved
SecobarbitalThe metabolism of Pitavastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Pitavastatin.Approved
SertralineThe serum concentration of Pitavastatin can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Pitavastatin can be decreased when combined with Sildenafil.Approved, Investigational
SimeprevirThe serum concentration of Pitavastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Pitavastatin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Pitavastatin can be increased when it is combined with Sirolimus.Approved, Investigational
SitaxentanThe serum concentration of Pitavastatin can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Pitavastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Pitavastatin.Investigational
SorafenibThe metabolism of Pitavastatin can be decreased when combined with Sorafenib.Approved, Investigational
SpiramycinThe risk or severity of adverse effects can be increased when Spiramycin is combined with Pitavastatin.Approved
St. John's WortThe metabolism of Pitavastatin can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Pitavastatin can be increased when it is combined with Stiripentol.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Pitavastatin.Approved
SulfadiazineThe metabolism of Pitavastatin can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Pitavastatin can be decreased when combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Pitavastatin can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Pitavastatin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Pitavastatin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Pitavastatin can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilThe serum concentration of Pitavastatin can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe metabolism of Pitavastatin can be decreased when combined with Tamoxifen.Approved
TelaprevirThe serum concentration of Pitavastatin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Pitavastatin can be increased when it is combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Pitavastatin can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Pitavastatin can be increased when it is combined with Teniposide.Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Pitavastatin.Approved
TerfenadineThe serum concentration of Pitavastatin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Pitavastatin can be increased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Pitavastatin.Experimental
TesmilifeneThe serum concentration of Pitavastatin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Pitavastatin can be increased when it is combined with Testosterone.Approved, Investigational
TetracyclineThe serum concentration of Pitavastatin can be increased when it is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pitavastatin.Investigational
ThiopentalThe serum concentration of Pitavastatin can be increased when it is combined with Thiopental.Approved, Vet Approved
TicagrelorThe metabolism of Pitavastatin can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Pitavastatin can be decreased when combined with Ticlopidine.Approved
TioclomarolPitavastatin may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe serum concentration of Pitavastatin can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Pitavastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TofisopamThe serum concentration of Pitavastatin can be increased when it is combined with Tofisopam.Approved
TolbutamideThe metabolism of Pitavastatin can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pitavastatin.Approved
TopiroxostatThe metabolism of Pitavastatin can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Pitavastatin can be increased when it is combined with Topotecan.Approved, Investigational
TrabectedinPitavastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe serum concentration of Pitavastatin can be increased when it is combined with Tramadol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Pitavastatin.Approved, Investigational
TranylcypromineThe serum concentration of Pitavastatin can be increased when it is combined with Tranylcypromine.Approved
TrimethoprimThe metabolism of Pitavastatin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TroglitazoneThe serum concentration of Pitavastatin can be increased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe serum concentration of Pitavastatin can be increased when it is combined with Troleandomycin.Approved
TromethamineThe serum concentration of Pitavastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Pitavastatin.Vet Approved
Valproic AcidThe metabolism of Pitavastatin can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Pitavastatin can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe serum concentration of Pitavastatin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Pitavastatin can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Pitavastatin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Pitavastatin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Pitavastatin can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Pitavastatin.Investigational
VoriconazoleThe metabolism of Pitavastatin can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinPitavastatin may increase the anticoagulant activities of Warfarin.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Pitavastatin.Approved
ZafirlukastThe metabolism of Pitavastatin can be decreased when combined with Zafirlukast.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pitavastatin.Approved
ZiprasidoneThe serum concentration of Pitavastatin can be increased when it is combined with Ziprasidone.Approved
ZucapsaicinThe serum concentration of Pitavastatin can be increased when it is combined with Zucapsaicin.Approved
Food Interactions
  • Avoid taking pitavastatin with red yeast rice. May increase risk of myopathy of pitavastatin via pharmacodynamic synergism. Red yeast rice contain monocolin K (similar to lovastatin)
  • Take with or without food

References

Synthesis Reference

Shriprakash Dhar DWIVEDI, Dhimant Jasubhai PATEL, Alpesh Pravinchandra SHAH, "METHOD FOR PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICAL ACCEPTABLE SALTS THEREOF." U.S. Patent US20120022102, issued January 26, 2012.

US20120022102
General References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]
  2. Jung JA, Noh YH, Jin S, Kim MJ, Kim YH, Jung JA, Lim HS, Bae KS: Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers. Clin Ther. 2012 Apr;34(4):958-65. doi: 10.1016/j.clinthera.2012.01.026. Epub 2012 Mar 10. [PubMed:22410289]
External Links
Human Metabolome Database
HMDB41991
KEGG Drug
D01862
KEGG Compound
C13334
PubChem Compound
5282452
PubChem Substance
175427122
ChemSpider
4445604
BindingDB
86707
ChEBI
32020
ChEMBL
CHEMBL1201753
PharmGKB
PA142650384
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pitavastatin
ATC Codes
C10AA08 — Pitavastatin
FDA label
Download (460 KB)
MSDS
Download (116 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentInfluenza in Humans1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHyperlipidemias / Hypertensive1
1CompletedOtherHyperlipidemias / Hypertensive1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentHypercholesterolaemia1
1CompletedTreatmentMetabolic Syndromes1
1Not Yet RecruitingTreatmentImpaired Renal Function1
1Unknown StatusNot AvailableHuman Immunodeficiency Virus (HIV) / Hyperlipidemias1
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Hypercholesterolaemia1
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia4
3CompletedTreatmentDyslipidemias / Hypercholesterolemia, Familial1
3CompletedTreatmentDyslipidemias / Hypertensive1
3CompletedTreatmentDyslipidemias / Type 2 Diabetes Mellitus2
3CompletedTreatmentHypercholesterolaemia1
3CompletedTreatmentHypercholesterolemia or Combined Dyslipidemia1
3TerminatedTreatmentDyslipidemias / Hyperlipidemias2
3Unknown StatusTreatmentHyperlipidemias1
4Active Not RecruitingBasic ScienceHealthy Volunteers1
4Active Not RecruitingTreatmentAnginal Pain / Atherosclerosis / Neointima1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD)1
4Active Not RecruitingTreatmentHbA1c Level Associated With Lipid Compositions1
4CompletedNot AvailableHealthy Volunteers3
4CompletedNot AvailableSevere Renal Impairment1
4CompletedTreatmentCardiovascular Risks / Hypertensive1
4CompletedTreatmentChronic Heart Failure (CHF)1
4CompletedTreatmentCoronary Artery Disease / Hypercholesterolaemia1
4CompletedTreatmentCoronary Heart Disease (CHD) / Hypercholesterolaemia2
4CompletedTreatmentDyslipidemias1
4CompletedTreatmentDyslipidemias / Human Immunodeficiency Virus (HIV)1
4CompletedTreatmentHypercholesterolaemia2
4CompletedTreatmentHypercholesterolaemia / Metabolic Syndromes1
4CompletedTreatmentHypercholesterolemia With Type2DM1
4CompletedTreatmentInflammatory Reaction / Metabolic Syndromes / Oxidative Stress1
4CompletedTreatmentMixed hypercholesterolemia / Primary Dyslipidemia1
4Not Yet RecruitingDiagnosticCoronary Artery Disease1
4Not Yet RecruitingTreatmentBMI >30 kg/m2 / Dyslipidemias1
4RecruitingPreventionCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusPreventionProphylaxis of Contrast-induced nephropathy1
4WithdrawnPreventionPercutaneous Coronary Intervention1
Not AvailableCompletedTreatmentHealthy Volunteers1
Not AvailableRecruitingNot AvailableInfection, Human Immunodeficiency Virus I1
Not AvailableRecruitingPreventionCoronary Artery Disease1
Not AvailableRecruitingTreatmentBMI >30 kg/m2 / Fatty Liver, Nonalcoholic1
Not AvailableTerminatedTreatmentAlzheimer's Disease (AD) / Hypercholesterolaemia1
Not AvailableUnknown StatusPreventionCardiovascular Disease (CVD)1
Not AvailableUnknown StatusTreatmentCarotid Artery Diseases / Hyperlipidemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral1.045 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral2.09 mg/1
Tablet, film coatedOral4 mg/1
Tablet, film coatedOral4.18 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6465477No2009-08-032016-12-20Us
US5753675No2009-08-032015-05-19Us
US5856336No2009-08-032016-01-05Us
US7022713No2009-08-032024-02-19Us
US5854259No2009-08-032015-12-29Us
US8557993No2004-02-022024-02-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP3.75ALOGPS
logP2.92ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)4.13ChemAxon
pKa (Strongest Basic)4.86ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area90.65 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity115.74 m3·mol-1ChemAxon
Polarizability43.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9735
Blood Brain Barrier+0.9296
Caco-2 permeable+0.5135
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.9015
P-glycoprotein inhibitor IINon-inhibitor0.9672
Renal organic cation transporterNon-inhibitor0.9101
CYP450 2C9 substrateNon-substrate0.7757
CYP450 2D6 substrateNon-substrate0.7668
CYP450 3A4 substrateNon-substrate0.5634
CYP450 1A2 substrateNon-inhibitor0.6867
CYP450 2C9 inhibitorNon-inhibitor0.7168
CYP450 2D6 inhibitorNon-inhibitor0.8695
CYP450 2C19 inhibitorNon-inhibitor0.8563
CYP450 3A4 inhibitorNon-inhibitor0.6855
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6481
Ames testNon AMES toxic0.837
CarcinogenicityNon-carcinogens0.9038
BiodegradationNot ready biodegradable0.997
Rat acute toxicity3.1821 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.987
hERG inhibition (predictor II)Non-inhibitor0.926
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-qTof , NegativeLC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Phenylquinolines
Direct Parent
Phenylquinolines
Alternative Parents
Phenylpyridines / Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Fluorobenzenes / Halogenated fatty acids / Heterocyclic fatty acids / Hydroxy fatty acids / Unsaturated fatty acids / Aryl fluorides
show 11 more
Substituents
Phenylquinoline / 4-phenylpyridine / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Fluorobenzene / Halobenzene / Halogenated fatty acid / Heterocyclic fatty acid / Hydroxy fatty acid
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines, statin (synthetic), cyclopropanes, dihydroxy monocarboxylic acid, monofluorobenzenes (CHEBI:32020)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46. Epub 2004 May 24. [PubMed:15159445]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46. Epub 2004 May 24. [PubMed:15159445]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA: Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8. doi: 10.1097/FJC.0b013e318256cdf0. [PubMed:22472908]

Drug created on March 03, 2013 16:50 / Updated on November 09, 2017 04:41